Solid Biosciences (SLDB) Non Operating Income (2017 - 2026)

Solid Biosciences has disclosed Non Operating Income across 10 years of filings, most recently posting $571000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $571000.0, up 203.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 3908.74% YoY), and the FY2025 annual result was $4.9 million, down 2.98% from the prior year.
• Non Operating Income came in at $571000.0 for Q1 2026 at Solid Biosciences, down from $4.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $19.4 million in Q4 2022 to a low of -$5.2 million in Q4 2023.
• The 5-year median for Non Operating Income is $722000.0 (2022), against an average of $1.8 million.
• Across the five-year window, Non Operating Income jumped 88350.0% in 2022 and sank 126.85% in 2023, its largest moves.
• Solid Biosciences' Non Operating Income stood at $19.4 million in 2022, then plunged by 126.85% to -$5.2 million in 2023, then jumped by 48.19% to -$2.7 million in 2024, then jumped by 258.31% to $4.3 million in 2025, then sank by 86.65% to $571000.0 in 2026.
• The last three Non Operating Income figures came in at $571000.0 (Q1 2026), $4.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.